TIDES Europe: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa

Lani Hack
Engineer II, ASO Formulation Development and Manufacturing at Biogen

Profile

Lani Hack has been an engineer in the Antisense Oligonucleotide Formulation Development and Manufacturing group at Biogen since 2017. Her primary responsibilities are on the drug product development team, where she is responsible for the development of candidate therapeutic molecules within the antisense oligonucleotide pipeline, from early stage clinical trials through commercial life cycle management.  Lani is also a member of the drug delivery team, directing the assessment of new delivery technologies to enhance the efficacy of oligonucleotide therapeutics for neurological indications. This work is driven through internal technical development initiatives and external collaborations. She is also responsible for developing novel biophysical characterization methods to assess physicochemical properties of oligonucleotides.

Lani holds a bachelor’s degree in Chemical Engineering from the University of California, Berkeley.

Lani Hack's Network

Agenda Sessions

  • Formulation and Process Parameter Development for the Terminal Sterilization of Antisense Oligonucleotide Drug Products

    , 16:15